+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Azithromycin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Azithromycin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Azithromycin Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082440
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Azithromycin Market grew from USD 7.40 billion in 2024 to USD 7.83 billion in 2025. It is expected to continue growing at a CAGR of 5.72%, reaching USD 10.34 billion by 2030.

Azithromycin has emerged as a cornerstone in antimicrobial therapy, offering broad-spectrum coverage across a diverse range of infections. Since its introduction, the drug has been recognized for its favorable safety profile, patient adherence benefits, and versatile dosing regimens. In recent years, evolving resistance patterns, shifting prescribing behaviors, and regulatory developments have combined to redefine its role within clinical practice. This executive summary provides a concise yet comprehensive overview of the current landscape, highlights transformative forces shaping future growth, and outlines critical insights across segmentation, regional dynamics, and competitive positioning. By synthesizing these elements, decision-makers and healthcare strategists will gain the clarity needed to navigate market complexities, optimize resource allocation, and capitalize on emerging opportunities in the azithromycin space.

Key Transformative Shifts Reshaping the Azithromycin Sector

The azithromycin market has undergone several pivotal shifts in recent years, driven by technological innovation, evolving antimicrobial stewardship guidelines, and enhanced patient-centric care models. Advances in rapid diagnostic testing are enabling clinicians to tailor azithromycin use more precisely, reducing unnecessary exposure and mitigating resistance. Simultaneously, digital health platforms are facilitating remote prescription and adherence monitoring, further expanding access while maintaining safety standards.

Regulatory trends have also had a profound impact. Stricter post-marketing surveillance requirements and updated labeling guidelines have prompted manufacturers to invest in pharmacovigilance and real-world evidence generation. This emphasis on safety data has strengthened stakeholder confidence, reinforcing azithromycin's position in treatment algorithms.

Moreover, strategic collaborations between pharmaceutical companies and biotechnology firms are driving novel formulation developments, such as extended-release and combination products, which enhance dosing convenience and patient compliance. Taken together, these transformative shifts are reshaping clinical practice, fostering market differentiation, and setting the stage for sustained therapeutic relevance.

Evaluating the Cumulative Impact of US Tariffs on Azithromycin in 2025

In 2025, newly enacted United States tariffs on imported active pharmaceutical ingredients and finished dosage forms have introduced significant cost pressures across the azithromycin supply chain. Raw material surcharges have led to increased production expenses for both domestic manufacturers and contract development organizations. This has, in turn, affected pricing negotiations between suppliers and major wholesalers, putting upward pressure on list prices and squeezing profit margins for generic players.

These tariffs have also catalyzed a strategic reevaluation of procurement strategies. Several manufacturers are exploring nearshoring or onshoring options to mitigate tariff exposure, investing in capacity expansion within North America. While this shift promises long-term supply chain resilience, it requires substantial capital investment and may extend time to market for new product launches.

Furthermore, the tariff-driven cost increases are influencing payer dynamics. Medical plans and pharmacy benefit managers are demanding enhanced value propositions, including outcome-based contracting and risk-sharing arrangements. Collectively, the cumulative impact of these measures underscores the need for agile supply chain management and proactive stakeholder engagement.

In-Depth Segmentation Analysis Reveals Targeted Growth Avenues

A granular segmentation framework reveals nuanced demand drivers across therapeutic, administrative, demographic, combination therapy, chemical class, formulation, prescription source, and care setting dimensions. Based on therapeutic application, the market comprises bacterial, ophthalmic, respiratory, sexually transmitted, and dermatological uses, each with further subcategories such as gastrointestinal, genitourinary, conjunctivitis, lower respiratory tract, chlamydia trachomatis, and acne vulgaris indications. Trends within these segments reflect varying prescribing patterns, from acute respiratory tract infections to chronic dermatological conditions.

When analyzing mode of administration, the exclusive focus on the oral route underscores the importance of formulation innovation to improve palatability, dosage accuracy, and patient adherence. Sex-specific prescriptions highlight the divergence in prescribing for female and male populations, influenced by differing infection prevalence and clinical trial representation.

Combination therapy strategies bifurcate into fixed-dose combinations and adjunctive regimens, the latter further divided into immunomodulators and steroids to enhance therapeutic efficacy. Within the drug class dichotomy of lincosamide-related versus macrolide antibiotics, azithromycin’s macrolide properties drive its competitive advantage through broader coverage and convenient dosing schedules.

Formulation types such as extended-release, powders for reconstitution, suspensions, and tablets cater to diverse patient needs, from pediatric to geriatric cohorts. Prescription sources-direct hospital, outpatient, and telemedicine-demonstrate shifting care pathways, with virtual consults gaining traction for uncomplicated infections. Finally, healthcare settings split between primary care and specialty clinics illuminate referral patterns and prescriber preferences, guiding targeted marketing and educational outreach efforts.

Regional Insights Highlight Divergent Market Dynamics

Regional dynamics in the azithromycin market exhibit notable heterogeneity. In the Americas, strong generic penetration and established distribution networks drive competitive pricing, while North American payers demand robust pharmacoeconomic evidence to justify formulary inclusion. Latin American markets, by contrast, show rising demand for branded products and improved cold-chain infrastructure, fueling brand differentiation efforts.

Across Europe, the Middle East & Africa, centralized procurement mechanisms and tender-based systems intensify price competition, prompting manufacturers to leverage real-world safety data and patient support programs. Reimbursement variances across EU member states and Gulf Cooperation Council countries create a mosaic of access levels, necessitating customized market entry strategies.

The Asia-Pacific region is characterized by rapid growth in telehealth and decentralized supply networks. Regulatory harmonization initiatives under regional economic partnerships are streamlining approval pathways, while local manufacturers are scaling production to meet domestic demand. In addition, rising awareness of antimicrobial stewardship is influencing guideline updates, creating opportunities for educational collaborations with health authorities.

Competitive Landscape: Leading Players and Strategic Positioning

The competitive landscape features global pharmaceutical heavyweights alongside specialized generics and biosimilar firms. Abbott's spin-offs and Amgen’s biologics-driven strategy emphasize diversified pipelines with potential intracellular delivery platforms for azithromycin. AstraZeneca’s recent collaborations highlight a commitment to innovation in combination therapies, while Aurobindo Pharma and Cipla focus on volume-driven growth in high-demand generic segments.

Major players such as Bayer and Bristol-Myers Squibb bring extensive R&D capabilities, driving novel formulation patents. Dr. Reddy’s Laboratories and Sun Pharmaceutical leverage cost-efficient manufacturing to maintain price leadership in emerging markets. Established brands like Eli Lilly and Company, Gilead Sciences, and GlaxoSmithKline emphasize strategic licensing and co-development agreements to expand therapeutic indications.

Johnson & Johnson, Merck & Co., Novartis, Pfizer, and Sanofi deploy integrated commercial models, combining direct sales forces with digital engagement platforms. Mylan, Sandoz, and Teva Pharmaceuticals are optimizing supply chain efficiencies to defend their generics portfolios, while specialty-focused firms explore niche applications and pediatric formulations. Collectively, these company strategies underscore the importance of agility, collaboration, and differentiated product offerings in securing market share.

Actionable Recommendations for Industry Leaders in Azithromycin

Industry leaders should prioritize integrated diagnostic partnerships to enhance stewardship and support targeted therapy. Investing in digital adherence tools will differentiate offerings and improve patient outcomes. Nearshoring production capabilities can mitigate future tariff risks, while collaborative risk-sharing agreements with payers will bolster value-based contracting.

To capitalize on emerging therapeutic niches, companies should expand combination therapy pipelines, focusing on immunomodulatory adjuncts in chronic infection management. Tailored educational initiatives across primary and specialty care settings will drive appropriate prescribing and reinforce brand credibility. Furthermore, regional market entry strategies must adapt to local procurement models, leveraging real-world evidence to navigate tender processes and reimbursement complexities.

Conclusion: Navigating Opportunities and Challenges in Azithromycin

Azithromycin’s longstanding clinical utility, coupled with evolving market dynamics, presents a compelling landscape of both opportunities and challenges. Stakeholders who proactively address supply chain vulnerabilities, invest in patient-centric innovations, and forge data-driven collaborations will be best positioned to sustain growth. By continuously monitoring regulatory changes, resistance trends, and payer expectations, organizations can refine strategic priorities and maintain therapeutic leadership in this essential antibiotic category.

Market Segmentation & Coverage

This research report categorizes the Azithromycin Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Bacterial Infections
    • Gastrointestinal Infections
    • Genitourinary Tract Infections
  • Ophthalmic Infections
    • Conjunctivitis
    • Keratitis
  • Respiratory Infections
    • Lower Respiratory Tract Infections
    • Upper Respiratory Tract Infections
  • Sexually Transmitted Infections
    • Chlamydia Trachomatis Infections
    • Mycoplasma Genitalium Infections
  • Skin Infections
    • Acne Vulgaris
    • Bacterial Dermatoses
  • Oral
  • Female Specific
  • Male Specific
  • Fixed-Dose Combinations
  • Therapy Adjuncts
    • Immunomodulators
    • Steroids
  • Lincosamide Related
  • Macrolide Antibiotics
  • Extended Release Formulations
  • Powders for Reconstitution
  • Suspensions
  • Tablets
  • Direct Hospital Prescriptions
  • Outpatient Prescriptions
  • Telemedicine Prescriptions
  • Primary Care
  • Specialty Clinics

This research report categorizes the Azithromycin Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Azithromycin Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie
  • Amgen
  • AstraZeneca
  • Aurobindo Pharma
  • Bayer
  • Bristol-Myers Squibb
  • Cipla
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Mylan
  • Novartis
  • Pfizer
  • Sandoz
  • Sanofi
  • Sun Pharmaceutical
  • Teva Pharmaceuticals

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Azithromycin Market, by Therapeutic Application
8.1. Introduction
8.2. Bacterial Infections
8.2.1. Gastrointestinal Infections
8.2.2. Genitourinary Tract Infections
8.3. Ophthalmic Infections
8.3.1. Conjunctivitis
8.3.2. Keratitis
8.4. Respiratory Infections
8.4.1. Lower Respiratory Tract Infections
8.4.2. Upper Respiratory Tract Infections
8.5. Sexually Transmitted Infections
8.5.1. Chlamydia Trachomatis Infections
8.5.2. Mycoplasma Genitalium Infections
8.6. Skin Infections
8.6.1. Acne Vulgaris
8.6.2. Bacterial Dermatoses
9. Azithromycin Market, by Mode of Administration
9.1. Introduction
9.2. Oral
10. Azithromycin Market, by Sex-Specific Prescriptions
10.1. Introduction
10.2. Female Specific
10.3. Male Specific
11. Azithromycin Market, by Combination Therapy
11.1. Introduction
11.2. Fixed-Dose Combinations
11.3. Therapy Adjuncts
11.3.1. Immunomodulators
11.3.2. Steroids
12. Azithromycin Market, by Drug Class
12.1. Introduction
12.2. Lincosamide Related
12.3. Macrolide Antibiotics
13. Azithromycin Market, by Formulation Type
13.1. Introduction
13.2. Extended Release Formulations
13.3. Powders for Reconstitution
13.4. Suspensions
13.5. Tablets
14. Azithromycin Market, by Patients By Prescription Source
14.1. Introduction
14.2. Direct Hospital Prescriptions
14.3. Outpatient Prescriptions
14.4. Telemedicine Prescriptions
15. Azithromycin Market, by Healthcare Setting
15.1. Introduction
15.2. Primary Care
15.3. Specialty Clinics
16. Americas Azithromycin Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Azithromycin Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Azithromycin Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie
19.3.2. Amgen
19.3.3. AstraZeneca
19.3.4. Aurobindo Pharma
19.3.5. Bayer
19.3.6. Bristol-Myers Squibb
19.3.7. Cipla
19.3.8. Dr. Reddy's Laboratories
19.3.9. Eli Lilly and Company
19.3.10. Gilead Sciences
19.3.11. GlaxoSmithKline
19.3.12. Johnson & Johnson
19.3.13. Merck & Co.
19.3.14. Mylan
19.3.15. Novartis
19.3.16. Pfizer
19.3.17. Sandoz
19.3.18. Sanofi
19.3.19. Sun Pharmaceutical
19.3.20. Teva Pharmaceuticals
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. AZITHROMYCIN MARKET MULTI-CURRENCY
FIGURE 2. AZITHROMYCIN MARKET MULTI-LANGUAGE
FIGURE 3. AZITHROMYCIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AZITHROMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AZITHROMYCIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2030 (%)
FIGURE 22. GLOBAL AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES AZITHROMYCIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES AZITHROMYCIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AZITHROMYCIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. AZITHROMYCIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AZITHROMYCIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AZITHROMYCIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AZITHROMYCIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AZITHROMYCIN MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AZITHROMYCIN MARKET SIZE, BY GENITOURINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AZITHROMYCIN MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AZITHROMYCIN MARKET SIZE, BY KERATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AZITHROMYCIN MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AZITHROMYCIN MARKET SIZE, BY UPPER RESPIRATORY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AZITHROMYCIN MARKET SIZE, BY CHLAMYDIA TRACHOMATIS INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AZITHROMYCIN MARKET SIZE, BY MYCOPLASMA GENITALIUM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AZITHROMYCIN MARKET SIZE, BY ACNE VULGARIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AZITHROMYCIN MARKET SIZE, BY BACTERIAL DERMATOSES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AZITHROMYCIN MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AZITHROMYCIN MARKET SIZE, BY FEMALE SPECIFIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AZITHROMYCIN MARKET SIZE, BY MALE SPECIFIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AZITHROMYCIN MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AZITHROMYCIN MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AZITHROMYCIN MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AZITHROMYCIN MARKET SIZE, BY LINCOSAMIDE RELATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AZITHROMYCIN MARKET SIZE, BY MACROLIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AZITHROMYCIN MARKET SIZE, BY EXTENDED RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AZITHROMYCIN MARKET SIZE, BY POWDERS FOR RECONSTITUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AZITHROMYCIN MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AZITHROMYCIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AZITHROMYCIN MARKET SIZE, BY DIRECT HOSPITAL PRESCRIPTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AZITHROMYCIN MARKET SIZE, BY OUTPATIENT PRESCRIPTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AZITHROMYCIN MARKET SIZE, BY TELEMEDICINE PRESCRIPTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AZITHROMYCIN MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AZITHROMYCIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 96. CANADA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 98. CANADA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 99. CANADA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 100. CANADA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 101. CANADA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 102. CANADA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 104. CANADA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 105. CANADA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 106. CANADA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. CANADA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 108. CANADA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 109. CANADA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 110. MEXICO AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. MEXICO AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 119. MEXICO AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES AZITHROMYCIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 168. CHINA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. CHINA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 170. CHINA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 171. CHINA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 172. CHINA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 173. CHINA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 174. CHINA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. CHINA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 176. CHINA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 177. CHINA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 178. CHINA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. CHINA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 180. CHINA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 181. CHINA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 182. INDIA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. INDIA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 184. INDIA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 185. INDIA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 186. INDIA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 187. INDIA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 188. INDIA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. INDIA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 190. INDIA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 191. INDIA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 192. INDIA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. INDIA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 194. INDIA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 195. INDIA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 210. JAPAN AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. JAPAN AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 212. JAPAN AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 213. JAPAN AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 214. JAPAN AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 215. JAPAN AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 216. JAPAN AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. JAPAN AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 219. JAPAN AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. JAPAN AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 222. JAPAN AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 223. JAPAN AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 294. THAILAND AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 295. THAILAND AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 297. THAILAND AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 298. THAILAND AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 299. THAILAND AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 300. THAILAND AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. THAILAND AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 302. THAILAND AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 303. THAILAND AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 304. THAILAND AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 305. THAILAND AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 306. THAILAND AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 307. THAILAND AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY RESPIRATORY INFECTIONS, 2018-2030 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2018-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY SKIN INFECTIONS, 2018-2030 (USD MILLION)
TABLE 328. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 329. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY SEX-SPECIFIC PRESCRIPTIONS, 2018-2030 (USD MILLION)
TABLE 330. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 331. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY THERAPY ADJUNCTS, 2018-2030 (USD MILLION)
TABLE 332. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 333. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 334. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY PATIENTS BY PRESCRIPTION SOURCE, 2018-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA AZITHROMYCIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 337. DENMARK AZITHROMYCIN MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. DENMARK AZITHROMYCIN MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 339. DENMARK AZITHROMYCIN MARKET SIZE, BY OPHTHALMIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 340. DENMARK AZITHROMYCIN MARKET SIZE,

Companies Mentioned

  • AbbVie
  • Amgen
  • AstraZeneca
  • Aurobindo Pharma
  • Bayer
  • Bristol-Myers Squibb
  • Cipla
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Mylan
  • Novartis
  • Pfizer
  • Sandoz
  • Sanofi
  • Sun Pharmaceutical
  • Teva Pharmaceuticals

Methodology

Loading
LOADING...

Related Topics

Related Reports

Azithromycin Market by Product Type, Distribution Channel, End User, Application, Therapeutic Area - Global Forecast 2025-2030 - Product Image

Azithromycin Market by Product Type, Distribution Channel, End User, Application, Therapeutic Area - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Azithromycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application - Product Image

Azithromycin Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application

  • Report
  • 113 Pages
  • Global
From
Azithromycin Dihydrate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2035F - Product Image

Azithromycin Dihydrate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2035F

  • Report
  • 183 Pages
  • Global
From
Azithromycin (CAS 83905-01-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Azithromycin (CAS 83905-01-5) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Macrolide Antibiotics Market Report 2025 - Product Image

Macrolide Antibiotics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Azithromycin Market

Azithromycin is an antibiotic used to treat a wide range of bacterial infections. It is a macrolide-type antibiotic, which works by stopping the growth of bacteria. Azithromycin is commonly used to treat respiratory infections, skin infections, ear infections, and sexually transmitted diseases. It is also used to prevent certain bacterial infections in people with weakened immune systems. Azithromycin is available in both oral and intravenous forms, and is often prescribed in combination with other antibiotics. Azithromycin is one of the most widely prescribed antibiotics in the world. It is generally well-tolerated and has a low risk of side effects. It is also relatively inexpensive, making it an attractive option for many patients. The azithromycin market is highly competitive, with many companies offering generic versions of the drug. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.